{"filing":{"accession_number":"0001453687-26-000090","cik":"0001453687","ticker":"RNAC","company_name":"Cartesian Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"rnac-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/rnac-20260612.htm"},"events":[{"id":11508,"run_id":10105,"accession_number":"0001453687-26-000090","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from the June 12, 2026 Annual Meeting of Stockholders, covering three proposals: election of three Class I directors (Michael Singer, Timothy Springer, and Patrick Zenner), advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing explicitly states the vote tallies and outcomes for each proposal, which is the core content of Item 5.07.","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8109,"accession_number":"0001453687-26-000090","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the June 12, 2026 Annual Meeting of Stockholders, covering three proposals: election of three Class I directors (Michael Singer, Timothy Springer, and Patrick Zenner), advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing explicitly states the vote tallies and outcomes for each proposal, which is the core content of Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:02:16.787632+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8109,"accession_number":"0001453687-26-000090","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the June 12, 2026 Annual Meeting of Stockholders, covering three proposals: election of three Class I directors (Michael Singer, Timothy Springer, and Patrick Zenner), advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing explicitly states the vote tallies and outcomes for each proposal, which is the core content of Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:02:16.787632+00:00","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-06-17"}]}